191 related articles for article (PubMed ID: 26055067)
1. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL; Januszewski AS; O'Connell R; Buizen L; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen MR; Rye KA; Keech AC;
Diabetologia; 2015 Sep; 58(9):2035-44. PubMed ID: 26055067
[TBL] [Abstract][Full Text] [Related]
2. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL; Januszewski AS; O'Connell R; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Hung WT; Scott RS; Taskinen MR; Keech AC; Rye KA
Diabetologia; 2015 Mar; 58(3):464-73. PubMed ID: 25425220
[TBL] [Abstract][Full Text] [Related]
3. Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study.
Ong KL; O'Connell R; Januszewski AS; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen MR; Waldman B; Colman PG; Best JD; Simes JR; Rye KA; Keech AC;
Clin Chem; 2017 Jul; 63(7):1261-1270. PubMed ID: 28606915
[TBL] [Abstract][Full Text] [Related]
4. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.
Ong KL; Rye KA; O'Connell R; Jenkins AJ; Brown C; Xu A; Sullivan DR; Barter PJ; Keech AC;
J Clin Endocrinol Metab; 2012 Dec; 97(12):4701-8. PubMed ID: 23144467
[TBL] [Abstract][Full Text] [Related]
5. The U-shaped relationship between fibroblast growth factor 21 and microvascular complication in type 2 diabetes mellitus.
Jung CH; Jung SH; Kim BY; Kim CH; Kang SK; Mok JO
J Diabetes Complications; 2017 Jan; 31(1):134-140. PubMed ID: 27839924
[TBL] [Abstract][Full Text] [Related]
6. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria.
Lee CH; Hui EY; Woo YC; Yeung CY; Chow WS; Yuen MM; Fong CH; Xu A; Lam KS
J Clin Endocrinol Metab; 2015 Apr; 100(4):1368-75. PubMed ID: 25625802
[TBL] [Abstract][Full Text] [Related]
7. Role of Circulating Fibroblast Growth Factor 21 Measurement in Primary Prevention of Coronary Heart Disease Among Chinese Patients With Type 2 Diabetes Mellitus.
Lee CH; Woo YC; Chow WS; Cheung CYY; Fong CHY; Yuen MMA; Xu A; Tse HF; Lam KSL
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28588089
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
9. The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study.
Ong KL; Wu L; Januszewski AS; O'Connell R; Xu A; Scott RS; Sullivan DR; Rye KA; Li H; Ma RC; Li L; Gebski V; Jenkins AJ; Jia W; Keech AC
Diab Vasc Dis Res; 2021; 18(4):14791641211032547. PubMed ID: 34275349
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Keech A;
Cardiovasc Diabetol; 2005 Aug; 4():13. PubMed ID: 16111499
[TBL] [Abstract][Full Text] [Related]
11. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study).
Ong KL; Hui N; Januszewski AS; Kaakoush NO; Xu A; Fayyad R; DeMicco DA; Jenkins AJ; Keech AC; Waters DD; Barter PJ; Rye KA
Metabolism; 2019 Apr; 93():93-99. PubMed ID: 30452928
[TBL] [Abstract][Full Text] [Related]
12. Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Williams KH; Sullivan DR; Veillard AS; O'Brien R; George J; Jenkins AJ; Young S; Ehnholm C; Duffield A; Twigg SM; Keech AC
Diabet Med; 2016 Mar; 33(3):356-64. PubMed ID: 26433207
[TBL] [Abstract][Full Text] [Related]
13. Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes.
Xiao Y; Liu L; Xu A; Zhou P; Long Z; Tu Y; Chen X; Tang W; Huang G; Zhou Z
Cardiovasc Diabetol; 2015 Jun; 14():72. PubMed ID: 26047614
[TBL] [Abstract][Full Text] [Related]
14. Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Chan KH; O'Connell RL; Sullivan DR; Hoffmann LS; Rajamani K; Whiting M; Donoghoe MW; Vanhala M; Hamer A; Yu B; Stocker R; Ng MK; Keech AC;
Diabetologia; 2013 Apr; 56(4):724-36. PubMed ID: 23322233
[TBL] [Abstract][Full Text] [Related]
15. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.
Mraz M; Bartlova M; Lacinova Z; Michalsky D; Kasalicky M; Haluzikova D; Matoulek M; Dostalova I; Humenanska V; Haluzik M
Clin Endocrinol (Oxf); 2009 Sep; 71(3):369-75. PubMed ID: 19702724
[TBL] [Abstract][Full Text] [Related]
16. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.
Rajamani K; Colman PG; Li LP; Best JD; Voysey M; D'Emden MC; Laakso M; Baker JR; Keech AC;
Lancet; 2009 May; 373(9677):1780-8. PubMed ID: 19465233
[TBL] [Abstract][Full Text] [Related]
17. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors.
Chow WS; Xu A; Woo YC; Tso AW; Cheung SC; Fong CH; Tse HF; Chau MT; Cheung BM; Lam KS
Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2454-9. PubMed ID: 23887638
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy.
Harmer JA; Keech AC; Veillard AS; Skilton MR; Marwick TH; Watts GF; Meredith IT; Celermajer DS;
Atherosclerosis; 2015 Sep; 242(1):295-302. PubMed ID: 26233916
[TBL] [Abstract][Full Text] [Related]
19. Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study.
Ong KL; Wu L; Januszewski AS; O'Connell RL; Xu A; Rye KA; Ma RCW; Li H; Jenkins AJ; Jia W; Keech AC;
Diabetes Res Clin Pract; 2020 Nov; 169():108450. PubMed ID: 32949655
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events.
Wu L; Qian L; Zhang L; Zhang J; Zhou J; Li Y; Hou X; Fang Q; Li H; Jia W
J Am Heart Assoc; 2020 Jun; 9(11):e015226. PubMed ID: 32431189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
